Nikki Martin on LUNGevity’s “No One Missed Campaign” Focusing on Biomarker Testing Access

Video

CancerNetwork® spoke with Nikki Martin of the LUNGevity Foundation regarding the “No One Missed” campaign working to provide education and awareness to patients with lung cancer.

CancerNetwork® recently spoke with Nikki Martin, director of Precision Medicine Initiatives at LUNGevity Foundation, regarding the recently launched No One Missed campaign.

The campaign focuses on helping patients gain access to valuable comprehensive biomarker testing, which can reveal the presence of driver mutations that are key in the treatment decision-making process.

“The No One Missed campaign is the latest evolution of our awareness and education programs for really targeting patients, but I can see how ultimately it could also become a provider-focused education and awareness campaign,” explained Martin. “what makes No One Missed unique is that it’s much broader than our previous education and awareness efforts. It’s a community-led program, so it’s not just LUNGevity Foundation running it, but we’re doing a lot more to pull in other stakeholders within the lung cancer ecosystem.”

LUNGevity Foundation is a nonprofit organization focusing on accelerating research and developing programs to remove barriers for patients with lung cancer accessing the necessary resources and care.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Related Content